Kuk Hyoun Hwang - 23 Mar 2023 Form 4 Insider Report for Bellevue Life Sciences Acquisition Corp. (OSRH)

Role
Chief Executive Officer, Director, 10%+ Owner
Signature
/s/ Kuk Hyoun Hwang
Issuer symbol
OSRH
Transactions as of
23 Mar 2023
Net transactions value
$0
Form type
4
Filing time
27 Mar 2023, 16:09:25 UTC
Previous filing
23 Feb 2023
Next filing
19 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BLAC Common Stock Other $0 -20,000 -0.99% $0.000000 2,000,500 23 Mar 2023 By Bellevue Global Life Sciences Investors LLC F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BLAC Warrant for Common Stock Other $0 -20,000 -5.1% $0.000000 370,000 23 Mar 2023 Common Stock 20,000 $11.50 By Bellevue Global Life Sciences Investors LLC F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock held by Bellevue Global Life Sciences Investors LLC the sponsor of the Issuer (the "Sponsor"), whose general partner is Bellevue Capital Management LLC ("Bellevue Capital"). Kuk Hyoun Hwang is the managing partner of Bellevue Capital and has voting and dispositive power over the shares held by the Sponsor.
F2 Represents the shares transferred by the Sponsor to Mr. David Jin Yoo for service as Chief Financial Officer.
F3 Represents the warrant to purchase a total of 20,000 shares of the Issuer, transferred from the Sponsor to Mr. David Jin Yoo for his service as Chief Financial Officer. Each warrant will become exercisable 30 days after the Issuer's initial business combination. Each warrant will expire five years after the completion of the Issuer's initial business combination, or earlier upon redemption or liquidation. Each warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share, subject to adjustments.